Although thyroid cells and pancreatic β cells may also undergo inflammatory destruction during ICI treatment (such as autoimmune thyroiditis with an incidence of approximately 10% and type 1 diabetes with a lower incidence of approximately 1%), this usually depends on a specific genetic susceptibility background (such as TPO antibody positivity or HLA susceptibility) and does not have broadly consistent target antigen characteristics like melanocytes (115). Here, TPO is linked to autoimmune thyroid disease.